Monitoring drug Efficacy through Multi-Omics Research initiative in Alzheimer’s Disease (MEMORI-AD): A protocol for a multisite exploratory prospective cohort study on the drug response-related clinical, genetic, microbial and metabolomic signatures in Filipino patients with Alzheimer’s disease
Introduction Dementia is one of the leading causes of disability among older people aged 60 years and above, with majority eventually being diagnosed with Alzheimer’s disease (AD). Pharmacological agents approved for dementia include acetylcholinesterase enzyme (AChE) inhibitors like rivastigmine, d...
Saved in:
| Main Authors: | Veeda Michelle M Anlacan, Fresthel Monica M Climacosa, Francis James A Gordovez, John Carlo B. Reyes, Ian Kim B Tabios, Rafael Vincent M Manalo, Joana Marie Ceripulo Cruz, Joannes Luke B Asis, Rozel B Razal, Mark Joseph M Abaca, Aira B Dacasin, Ayra Patrice N Espiritu, Nicole Clarence Louise L Gapaz, Melody Hope L Lee Yu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/11/e078660.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alzheimer's disease drug development pipeline: 2022
by: Jeffrey Cummings, et al.
Published: (2022-01-01) -
AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery
by: Frances M. Potjewyd, et al.
Published: (2022-01-01) -
Alzheimer's disease drug development in an evolving therapeutic landscape
by: Stacie Weninger, et al.
Published: (2024-10-01) -
Unveiling Cathepsin B inhibition with repurposed drugs for anticancer and anti-Alzheimer's drug discovery.
by: Mohammed Alrouji, et al.
Published: (2024-01-01) -
Non-Drug and Non-Invasive Therapeutic Options in Alzheimer’s Disease
by: Alina Simona Șovrea, et al.
Published: (2025-01-01)